Select products from Pfizer, Eli Lilly and others will be sold at a discount, although the lower costs won’t be felt by many ...
CagriSema’s blood sugar and weight reductions exceeded the company’s blockbuster Wegovy, yet the drug might still struggle to ...
AstraZeneca’s investment will “span the value chain” of drug research and development and comes amid a prolonged surge in ...
The agency’s program will be open to pharmaceutical facilities that align with “national priorities.” Elsewhere, a ...
Still, the medications in the latest round of negotiations — which now includes “Part B” drugs given in doctors offices — ...
On a Monday conference call, Sarepta CEO Doug Ingram said new long-term data should help “rebalance the discussion” surrounding Elevidys.
In contrast to Lilly’s optimistic forecasts, Novo cited pricing constraints and competitive pressure in predicting up to a 13 ...
Data integrity is key to the success of any cell therapy program. CDMOs can implement robust data management systems for ...
A massive overhaul of staffing and review processes have left the agency appearing heavily driven by the Trump administration ...
The biotech also raised $235 million in debt and equity funding to support marketing of the drop, which it claims to be an ...
On a conference call, executives cited “confusion” and declining vaccination rates in the U.S. while discussing a quarterly sales decline and anticipated slower growth in 2026.
A long-acting shot Pfizer got through a buyout of Metsera appeared “slightly inferior” to Lilly’s market-leading Zepbound in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results